Stress cardiomyopathy: clinical and ventriculographic characteristics in 107 North American subjects.

BACKGROUND: Stress cardiomyopathy (SCM) is a newly described reversible cardiomyopathy of largely unclear etiology. We studied SCM in a large cohort to gain further insights. METHODS: We retrospectively identified 114 cases of SCM from among 12,150 consecutive North American patients diagnosed as Troponin-positive acute coronary syndrome, from January 2000 through December 2007, at two 24-h coronary angioplasty-capable centers. Left ventriculographic wall contractility was analyzed and scored in 107 patients on the right anterior oblique view. RESULTS: In 107 patients (66+/-14 years, 99 females), variable regional contractility or "ballooning" was observed including: postero-basal, 1%; basal+mid-ventricular, 1%; diaphragmatic, 2%; localized apical, 2%; antero-lateral, 11%; complete mid-ventricular, 29%; and classical variant, 54%. The localized and complete mid-ventricular variants (n=45, 40 females) had a younger median age at presentation (64 vs. 71 years, p=0.008) and higher median LV ejection fraction (45% vs. 35%, p=0.006) than the classical or tako-tsubo variants (n=58, 55 females) with similar baseline exposure to stressors, risk factor and in-hospital complications. Frequency of involvement and mean contractile score (dysfunction) of the antero-lateral segment was significantly (p<0.05) greater in the order, antero-lateral>diaphragmatic>apical>basal. CONCLUSION: From a single large cohort of SCM, evidence on significant individual variation in clinical and morphological pattern was confirmed. Frequency and vulnerability to transient dysfunction differs within segments with antero-lateral involvement significantly greater than diaphragmatic, apical, basal-anterior and basal-posterior LV segments. Further studies in phenotype should be undertaken for proper identification, classification and pathophysiological implications.

Angiotensin-converting enzyme inhibitor use in elderly patients hospitalized with heart failure and left ventricular systolic dysfunction.

PURPOSE: Although angiotensin-converting enzyme (ACE) inhibitors are recommended for all patients with systolic heart failure, prior studies suggest that elderly cohorts are less likely to receive such therapy. The purpose of this study was to determine the age dependence of adherence to guideline-based medical care in hospitalized heart failure patients. METHODS: We performed a multicenter observational cohort study including 613 patients admitted to participating hospitals with a primary diagnosis of heart failure with ejection fraction < or =40%. This cohort was divided into four age groups (group 1: <60, group 2: 60-69, group 3: 70-79, and group 4: 80 years) and adherence to guideline-based medical care was measured. RESULTS: ACE inhibitors were administered to 83% of ideal heart failure patients, and this rate was similar for all age groups. Elderly patients received significantly lower ACE inhibitor dosages compared to their younger counterparts (168, 148, 125 and 117 mg captopril in groups 1, 2, 3, and 4, respectively, p=0.001). Lower creatinine clearance (p<0.001), prior residence in a long-term care facility (p=0.037), intolerance to ACE inhibitors (p=0.006), lower blood pressure (p=0.005), absence of a history of hypertension (p=0.005), and no prior heart failure hospitalizations within the past year (p=0.001) were found to be independent predictors of low ACE inhibitor dosing. CONCLUSIONS: In this heart failure benchmarking project, elderly patients received guideline-based ACE inhibitor therapy at similar rates, but at lower doses, compared to their younger counterparts.

Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia.

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a common, often catastrophic, syndrome that produces the most hypercoagulable of states. Emerging therapeutic strategies use alternative anticoagulants; warfarin's place is being reexamined. Early in the course of warfarin therapy, there may be net procoagulant effects because of the inhibition of protein C. With HIT, it has been suggested that unopposed warfarin can precipitate venous limb gangrene. There are also reports of warfarin-induced skin necrosis. We seek to confirm and increase awareness of the risks of warfarin with HIT. METHODS: We describe 6 patients with HIT seen at 3 medical centers in whom frank or impending venous limb gangrene, central skin necrosis, or both were temporally related to warfarin initiation. RESULTS: At warfarin initiation, 5 patients had recognized HIT and 1 had it recognized later. Complications emerged after 2 to 7 days, and consisted of warfarin-induced skin necrosis (n = 5) and venous limb gangrene (n = 2); 1 patient had both. This emerged with unopposed warfarin in 4 patients and as a direct thrombin inhibitor was being withdrawn in 2. All had supratherapeutic international normalized ratios. One patient required leg and breast amputations, and another one died. CONCLUSIONS: Because of the early effects on protein C, warfarin can precipitate venous limb gangrene and/or skin necrosis in the extreme hypercoagulable milieu of HIT. With HIT, unopposed warfarin should be avoided and caution is needed during transition from a direct thrombin inhibitor. Warfarin should be initiated at modest doses in patients with HIT after platelet recovery. Implications extend to warfarin initiation with other thrombotic diatheses.